Finanzen von LakeShore Biopharma Co Ltd (LSB)LSBLakeShore Biopharma Co Ltd

Evaluating the bottom line, LakeShore Biopharma Co Ltd maintains a gross margin of 82.61%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.30%, while the net margin is 5.53%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively LSB converts its operational activities into shareholder value.

In the context of the broader market, LSB competes directly with industry leaders such as SABS and BOLD. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, LSB's gross margin of 82.61% stands against SABS's N/A and BOLD's N/A. Such benchmarking helps identify whether LakeShore Biopharma Co Ltd is trading at a premium or discount relative to its financial performance.